Syapse

Precision cancer company Syapse is teaming with Seoul National University Hospital and Asian AWS partner Megazone

Pharmaceutical giant Roche has entered into a collaboration with Syapse to widen access to precision oncology technology and services.

Syapse has raised new venture capital to support expansion into community hospitals that want to start precision oncology programs.

Through the deal, Sylvester will have access to Syapse's precision medicine platform for cancer care.

The agreement lets Biotheranostics offer its CancerType ID and Breast Cancer Index genomic tests to customers through Syapse's software.

The two health systems have also joined the OPeN consortium and plan to share cancer patient data in support of the Cancer Moonshot Initiative. 

Within the consortium community healthcare systems can contribute and access each other's data on cancer patients' molecular profiles and treatment outcomes.

The consortium aims to share aggregated data between its members, enabling more cancer patients to benefit from high volume-based analytics.

The company is seeking partnerships that will enable it to offer its software to more users as part of larger, more integrated systems. 

Syapse is using the Series C funding to hire new staff and extend its Syapse Precision Medicine platform to support disease areas beyond cancer.

Pages

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.